Potential for parenthood is good for adult female survivors of Hodgkin lymphoma
the ONA take:
A prospective, longitudinal study involving 590 female patients younger than 18 years at diagnosis who participated in one of five Hodgkin lymphoma treatment studies between June 19, 1978, and July 12, 1995, were the cohort in a study to assess the frequency for parenthood in female survivors of Hodgkin lymphoma. Parenthood was defined as delivery of a liveborn child.
The control group was the German female population age 16-49 years, using data from the 2012 Mikrozensus population survey.
Of the 590 patients in the cohort, 467 had long-term follow-up (median 20.4 years) and were in continuous remission. Of these patients, 228 patients had 406 children.
Cumulative incidences of parenthood were 67% at 27.7 years follow-up (longest period of follow-up at birth of first child) and 69% at age 39.8 years (oldest age of patient at birth of first child).
Parenthood was significantly lower among survivors who received pelvic radiation compared with those who received abdominal and supradiaphragmatic radiation, and parenthood in women age 40-44 years at the time of last information was lower than in women the same ages in the general population.
The results indicate a favorable prognosis for parenthood in female survivors of Hodgkin lymphoma. The researchers suggest counseling for female survivors should include this positive potential for future parenthood.
Parenthood was significantly lower among Hodgkin lymphoma survivors who received pelvic radiation.
- Cholesterol-Lowering Drugs May Prevent Breast Cancer Recurrence
- BBD Regimen Efficacious as First-line Therapy for Myeloma
- Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- Decipher Genomic Classifier Prognostic for Distant Prostate Metastasis
- GUCS 2017: Adjuvant Trials in Post-radical Prostatectomy Prostate Cancer Feasible
- Annual Screening of High-Risk Smokers Only More Cost-effective Than Current Methods
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Metronomic Chemotherapy: Improved Tumor Blood Supply Leads to Better Treatment
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|